Podcasts about Pharma

(0:00) Commerce Secretary Howard Lutnick tells a hilarious Air Force One story (2:24) Chamath intros Secretary Lutnick (7:28) Full scope of the Commerce Department (12:59) How Trump's tariff agenda was planned and executed, how it's going (19:50) US-Japan trade deal, China's chaos-to-prowess strategy (36:54) Why the India deal has not yet happened (43:48) Pharma deals, lowering costs for Americans (53:28) Focus on fraud, immigration, gold cards (1:03:48) GDP: Could we see 5 or 6% growth in 2026? (1:11:49) How the Trump Admin revamped the CHIPS Act, Nvidia deal Follow Secretary Lutnick: https://x.com/howardlutnick Follow the besties: https://x.com/chamath https://x.com/Jason https://x.com/DavidSacks https://x.com/friedberg Follow on X: https://x.com/theallinpod Follow on Instagram: https://www.instagram.com/theallinpod Follow on TikTok: https://www.tiktok.com/@theallinpod Follow on LinkedIn: https://www.linkedin.com/company/allinpod Intro Music Credit: https://rb.gy/tppkzl https://x.com/yung_spielburg Intro Video Credit: https://x.com/TheZachEffect

Today's guest is Vaithi Bharath, Associate Director of Data Science & AI Solutions at Bayer. Bharath joins Emerj Editorial Director Matthew DeMello to break down why clinical R&D timelines often slip for reasons that have little to do with model performance. Rather, delays compound when data moves across fragmented systems, teams rely on slow handoffs, and validation requirements turn minor adjustments into major cycle-time hits. He walks through where decision-making slows from data capture through database lock, and what it takes to accelerate workflows without replacing a validated environment. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the 'AI in Business' podcast! This episode is sponsored by AnswerRocket.

Trevor Maxwell lived the archetype of masculinity in rural Maine. Big, strong, splitting wood, raising kids, and carrying the load. Then cancer ripped that script apart. In 2018 he was bedridden, emasculated, ashamed, and convinced his family would be better off without him. His wife refused to let him disappear. That moment forced Trevor to face his depression, get help, and rebuild himself. Out of that came Man Up To Cancer, now the largest community for men with cancer, a place where men stop pretending they are bulletproof and start being honest with each other.Eric Charsky joins the conversation. A veteran with five cancers, forty-nine surgeries, and the scars to prove it, Eric lays out what happens when the military's invincible mindset collides with mortality. Together, we talk masculinity, vulnerability, sex, shame, and survival. This episode is blunt, raw, and overdue.RELATED LINKSMan Up To CancerTrevor Maxwell on LinkedInDempsey CenterEric Charsky on LinkedInStupid Cancer FEEDBACKLike this episode? Rate and review Walk It Off on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Advancing longevity research is about honoring the value of life—and translating that respect into evidence-based prevention. If healthcare is judged by life expectancy + quality of life, longevity medicine may be one of the most meaningful metrics we can pursue: extending health span through early detection, validated biomarkers, and interventions that scale.This unforgettable Expert Panel from the 4th annual Medical Innovation Olympics (#MIO2025) convened all-star global leaders in Longevity and Preventive Medicine who separated hype from reality and outlined what it will take to bring longevity into mainstream care - rigorously, ethically, and accessibly.Topics include: breakthroughs (including epigenetic approaches pointing toward functional restoration of eyesight), biomarkers/endpoints as the “keystone” for faster trials, the TAME (Targeting Aging with Metformin) concept, and the role of standards, education, trust, and shared responsibility—keeping dignity central.Panelists:Dr. David Barzilai (Harvard Medical School; Geneva College of Longevity Science, GCLS) • Dr. Dominik Thor (President, GCLS) • Dr. Mishkat Shehata (Emirates Lifestyle & Longevity Medicine Society) • Keith Comito (Lifespan Research Institute) • Dr. Uma Senthilkumar (Three Five Revive)

The Nurses Report on America Out Loud with Nicole, David & Ashley – A global pharmaceutical giant's China operation descends into bribery, espionage, and hidden-camera scandal, exposing familiar patterns of corporate corruption, regulatory failure, and human cost as whistleblowers, executives, and investigators collide with state power and unchecked pharmaceutical influence...

The Nurses Report on America Out Loud with Nicole, David & Ashley – A global pharmaceutical giant's China operation descends into bribery, espionage, and hidden-camera scandal, exposing familiar patterns of corporate corruption, regulatory failure, and human cost as whistleblowers, executives, and investigators collide with state power and unchecked pharmaceutical influence...

► Jetzt von der einmaligen Rendite-Spezialisten-Neujahrsaktion profitieren: http://rendite-spezialisten.de/vorteil - 30 Tage Geld-Zurück-Garantie
 Wir starten mit Pauken und Trompeten in das Jahr 2026. Heute möchte ich gemeinsam mit euch einen Deep Dive in Novo Nordisk machen. Es ist kein unrealistisches Szenario, dass sich die Aktie in diesem Jahr verdoppelt oder zumindest mehr als fünfzig Prozent an Wert gewinnt. Wichtig vorab der Disclaimer: Ich bin selbst mit einer Zockerposition investiert und wünsche mir daher, dass genau das eintritt, was ich im Folgenden bespreche.
 ► Hole dir jetzt deinen Zugang zur brandneuen BuyTheDip App! Jetzt anmelden & downloaden: http://buy-the-dip.de
 ► An diese E-Mail-Adresse kannst du mir deine Themen-Wünsche senden: podcast@lars-erichsen.de
 ► Meinen BuyTheDip-Podcast mit Sebastian Hell und Timo Baudzus findet ihr hier: https://buythedip.podigee.io
 Viel Freude beim Anhören. Über eine Bewertung und einen Kommentar freue ich mich sehr. Jede Bewertung ist wichtig. Denn sie hilft dabei, den Podcast bekannter zu machen. Damit noch mehr Menschen verstehen, wie sie ihr Geld mit Rendite anlegen können.
 ► Mein YouTube-Kanal: http://youtube.com/ErichsenGeld
 ► Folge meinem LinkedIn-Account: https://www.linkedin.com/in/erichsenlars/
 ► Folge mir bei Facebook: https://www.facebook.com/ErichsenGeld/
 ► Folge meinem Instagram-Account: https://www.instagram.com/erichsenlars
 Die verwendete Musik wurde unter www.soundtaxi.net lizenziert. 
Ein wichtiger abschließender Hinweis: Aus rechtlichen Gründen darf ich keine individuelle Einzelberatung geben. Meine geäußerte Meinung stellt keinerlei Aufforderung zum Handeln dar. Sie ist keine Aufforderung zum Kauf oder Verkauf von Wertpapieren.
 Zum Zeitpunkt der Erstellung dieses Beitrags war der Autor, Lars Erichsen, in folgenden der besprochenen Finanzinstrumente selbst investiert: Novo Nordisk. Geplante Änderungen: Keine. Weitere Informationen entnehmen Sie bitte unserem Transparenzhinweis zum Umgang mit Interessenskonflikten: https://www.lars-erichsen.de/transparenz-und-rechtshinweis

In this conversation, career ownership coach Maja Taylor shares powerful insights on what it truly means to take control of your professional future. She talks about helping leaders and professionals explore new career paths, including entrepreneurship, so they can maximize their potential and build careers that fully align with their goals and values. Maja encourages listeners to regularly review their career direction, consider alternative income streams and stay open to possibilities that may lead to greater fulfillment and independence. Employee Engagement and the Need for Better Guidance Michael discusses the growing disconnect many employees feel in today's workplace and highlights how small businesses and leaders can play a pivotal role in guiding their teams toward greater engagement and clarity. He emphasizes the value of career exploration and meaningful conversations that help individuals uncover interests, strengths and untapped potential. Michael also shares personal stories about stepping into new roles without a perfect plan and learning through adaptability, curiosity and experience. Navigating Burnout and Workplace Uncertainty Maja speaks candidly about the rising rates of burnout she sees among clients, driven by layoffs, constant change and market instability. She explains how her coaching practice supports individuals during these challenging transitions by helping them rediscover confidence, purpose and possibility. Maja also reflects on her own journey from science to HR to leadership coaching, revealing how each chapter deepened her passion for helping others achieve greater self sufficiency and work life balance. Corporate Experience as a Launchpad for Entrepreneurship Michael reminds listeners that entrepreneurship is rarely about starting from zero. Skills gained in corporate environments, from operational insight to relationship building, can become powerful assets when launching a business. He encourages people to recognize the value of their existing expertise and leverage it instead of discounting it. Career Coaching for the Shift Into Business Ownership Maja outlines her approach to coaching professionals who are evaluating entrepreneurship, especially those who feel drained by corporate roles or stuck in burnout cycles. She uses assessments to help clients recognize their strengths and potential, and stresses the importance of being open minded as they explore ownership opportunities. Michael adds that many people underestimate their abilities due to work environments that suppress creativity and curiosity. Curiosity as a Catalyst for Breakthroughs Michael shares a personal story about taking a personality assessment with his former CEO and discovering they shared the same profile. The experience reminded him that curiosity is a powerful driver of self awareness and growth. He encourages listeners to lean into curiosity as a tool for breakthroughs, career shifts and life changing clarity. Goal Setting, Reflection and a Free DISC Assessment Maja talks about the impact of written goals, noting that only a small percentage of people write down their goals, yet nearly all who do achieve them. She offers a complimentary executive DISC assessment to help listeners better understand their personality patterns and career strengths. Michael encourages everyone to take advantage of the offer and reminds listeners that Maja's contact information and social links are included in the show notes below.   Maja Taylor is a Career Ownership Coach with The Entrepreneur's Source, where she guides people who are ready to step outside the traditional job market and into new possibilities. She supports clients as they explore entrepreneurship, business ownership, investments, licensing, and franchising, helping them design a career path that aligns with their values, strengths and long term vision. Maja is driven by a deep passion for personal transformation and lifelong learning. She thrives on watching clients experience those pivotal AHA moments when they realize what they are truly capable of. Her mission is to help people rise to their full potential by building careers and businesses that reflect who they are and the life they want to create. With a foundation in science education and talent development, Maja has worked across Europe and the United States in global organizations as a team leader, scientist, strategic HR professional, trainer, coach and mentor. She brings a unique blend of analytical thinking, people development expertise, and business strategy to every client engagement. Her work focuses on helping individuals grow their dreams, wealth and personal equity as they move toward self sufficiency and higher levels of fulfillment and success. Background Overview • Business Owner and Certified Professional Coach • Global Talent, Learning and Engagement roles in Pharma and Biotech • Management consulting experience with Fortune 500 organizations • Scientific and HR leadership roles in manufacturing and environmental industries • Education: BS in Pharmacy, University of Applied Sciences, Wiesbaden, Germany • Credentials: Certified Coach, Human Resources Professional, Leadership Trainer and Facilitator; certified in DiSC, 360 assessments and multiple professional development tools Connect with Maja Website: www.majataylor.esourcecoach.com Email: majataylor@esourcecoach.com LinkedIn: https://www.linkedin.com/in/majataylor/ Facebook: https://www.facebook.com/majataylorcoach Instagram: https://www.instagram.com/majataylorcoach For your audience, add to captions, free offer – DiSC assessment with debrief - a $200 value – if your listeners reach out to me on social media/LI/Insta/FB/ or my website and book a call at www.majataylor.esourcecoach.com

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Jim Gale, Founding Partner & Managing Director at Signet.   Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jim, covering: The origins of growth equity in private equity and how it led to the founding of Signet, a fund built on deep domain expertise. Why private equity is a growing asset category but still remains undervalued and under appreciated. How the nature of the companies Signet invests in has evolved over the last twenty five years, while the fundamental principles of building a strong business remain the same. How the “picks and shovels” strategy of investing in tools, services and infrastructure has consistently served them well. Jim's assessment criteria when evaluating new opportunities after seventy deals, including the key question… can we institutionalise an entrepreneur led business. How higher interest rates and economic uncertainty constrain biopharma and biotech, and how that impacts investment dollars flowing into pharma services, along with deal flow, valuation and structure. James “Jim” Gale is the Founding Partner and Managing Director of Signet Healthcare Partners, a New York based healthcare growth equity firm specialising in pharmaceutical services, specialty pharma and medical technology. With more than thirty five years of investing and finance experience, Jim has built a deep track record backing companies involved in formulation, development, manufacturing and commercialisation across the world.   At Signet, Jim has led investments across the pharma services value chain, including platforms in sterile fill finish, complex formulations, biologics development and specialty generics. His current and recent board roles include Ascendia Pharmaceutical Solutions, NorthX Biologics, RK Pharma, Bionpharma, Chr Olesen Synthesis, Pharma Nobis, Juno Pharmaceuticals and Lee's Pharmaceutical. He also serves as Chairman of Bionpharma and is a director of Knight Therapeutics.   Jim holds an MBA from the University of Chicago Booth School of Business.   Molecule to Market is also sponsored by Bora Pharmaceuticals and Charles River Laboratories, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!

Kailera jumped the weight loss miracle-drug line by licensing four clinical-stage obesity therapies from China, which is quickly emerging as a powerhouse pharmaceutical R&D center. After all, why spend millions trying to develop novel medications in the U.S. when Chinese firms have probably already done it for you? See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

One on One Video Call W/George https://tidycal.com/georgepmonty/60-minute-meetingSupport the show:https://www.paypal.me/Truelifepodcast?locale.x=en_USIn this powerful episode of the True Life Podcast, host George Monty delivers a hard-hitting “daily transmission” exposing how corporations and systems deliberately manufacture scarcity to drive profits, control populations, and prevent true abundance from reaching everyday people. Drawing on real-world examples from food, housing, medicine, and more, George reveals the patterns of consolidation, surplus destruction, and artificial shortages that keep society desperate and divided. He calls for recognition, documentation, and rebellion against this “scarcity weapon,” urging listeners to investigate local resources and demand the withheld plenty. This episode is a wake-up call to see beyond the narratives of inflation and supply chain issues to the engineered theft of abundance.Host: George MontyPodcast: True Life PodcastDuration: Approximately 10-15 minutes (based on transcript length)Release Date: Estimated based on content references (late 2025)Listen Here: Explore more episodes and connect with George Monty on the TrueLife platform. Key Timestamps & HighlightsGeorge's monologue flows as a continuous narrative, but we've broken it down into thematic sections with approximate timestamps for easy navigation:•  00:00 - 01:00: The Illusion of Struggle George opens by challenging the narrative that you're failing—it's engineered starvation in abundance. He prompts listeners to check their finances and see how earnings vanish despite higher pay, labeling it “2025's manufactured scarcity” designed for control and extraction.•  01:00 - 02:30: From Ancient Famines to Modern Engineering Contrasting natural famines with today's deliberate hunger, George highlights U.S. food production capacity (enough for 10 billion people) versus 34 million facing food insecurity amid record corporate profits.   He exposes the “machine that weaponizes emptiness.” •  02:30 - 04:00: Food Shortages Exposed•  2024 egg shortage: Not avian flu, but corporate consolidation by Cal-Maine Foods (20% market control), leading to tripled prices and $535 million in profits. •  2022-2024 baby formula crisis: Abbott's monopoly (43% market) caused shutdowns, boosting stock 34% while parents turned to black markets. https://www.theguardian.com/us-news/2025/apr/09/doj-egg-prices-rise-cal-maine-profits•  04:00 - 05:00: Housing and Tech Hoarding•  Housing crisis: 16 million vacant homes in the U.S. versus over 600,000 homeless, as empty properties prove more profitable. •  2025 semiconductor shortage: TSMC's alleged deliberate restrictions via leaked emails to maintain pricing, with chips stockpiled while car prices soar.  (Note: Related to trade secret leaks; broader shortage context available.)https://unitedwaynca.org/blog/vacant-homes-vs-homelessness-by-city/•  05:00 - 06:30: Surplus Destruction and Corporate Mandates George uncovers patterns of destroying goods under USDA/EPA/FDA protocols lobbied by corporations.  He cites the 2024 NASS report (Appendix G, p. 847) on 2.3 billion pounds of produce destroyed to avoid “market destabilization.”  Kroger's 2019 leaked memo advocates “optimal scarcity ratios” for urgency buying. https://www.usda.gov/about-usda/news/press-releases/2023/09/20/usda-expands-efforts-prevent-and-reduce-food-loss-and-wastehttps://www.nass.usda.gov/Charts_and_Maps/Crop_Progress_&_Condition/2024/index.phphttps://www.nationofchange.org/2024/09/03/corporate-greed-exposed-kroger-admits-to-price-gouging-on-milk-and-eggs-amid-antitrust-trial/•  06:30 - 08:00: The Scarcity Playbook Step-by-step breakdown: Consolidate supply, engineer shortages (restrict, destroy surplus), profit from desperation. Blame shifts to weather or labor, not architects.•  08:00 - 10:00: Historical and Ongoing Examples•  2008 housing crisis: Banks held 3.5 million foreclosures as “shadow inventory” to keep prices high. https://en.wikipedia.org/wiki/Subprime_mortgage_crisis•  2020 toilet paper: Procter & Gamble and Georgia-Pacific (55% control) restricted distribution for 300% price surges at 64% capacity. https://www.resourcewise.com/market-watch-blog/are-we-really-running-out-of-toilet-paper-in-the-covid-crisis•  2021 lumber: Weyerhaeuser and West Fraser (40% control) quadrupled prices with underused mills. https://markets.businessinsider.com/news/stocks/lumber-prices-hit-record-highs-soaring-past-year-2021-4-1030299977•  2023 prescription drugs: Wholesalers like McKesson, Cardinal, and AmerisourceBergen (95% control) restrict insulin ($2 production cost) amid shortages. https://www.mmm-online.com/home/channel/drug-shortages-in-america/•  2025 water: Nestlé, Coca-Cola, Pepsi (75% bottled water) amid contaminated public supplies. https://www.grandviewresearch.com/industry-analysis/bottled-water-market•  10:00 - 11:30: Broader Patterns of Waste Amazon destroys 2 million unsold products yearly for scarcity pricing.  Pharma discards effective expired meds.  Energy firms flare gas for 10 million homes.  McKinsey's 2023 report recommends 15-20% below-demand inventory for margins.  Supply chain “disruptions” post-2020? Traffic normalized by Q3 2021, but prices stayed high via throttling. https://www.ethicalconsumer.org/ethical-campaigns-boycotts/amazons-burning-approach-unsold-returned-productshttps://pmc.ncbi.nlm.nih.gov/articles/PMC10834166/

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some fascinating updates that are shaping the future of medicine and healthcare.Let's start with a groundbreaking development in cancer treatment. Researchers have announced significant progress in a novel therapy targeting a specific mutation often found in non-small cell lung cancer. This mutation, known as EGFR exon 20 insertion, has historically been resistant to standard treatments. The new therapy employs a targeted approach that precisely inhibits the mutant protein while sparing normal cells. Early-phase clinical trials have shown promising results, with substantial tumor shrinkage observed in participants. This could potentially redefine treatment protocols for patients who previously had limited options and improve their overall survival rates. As the study progresses into later phases, the industry is watching closely to see if these initial successes translate into long-term benefits.In another significant development, we're seeing advancements in gene therapy for inherited retinal diseases. A recent study has highlighted a novel gene-editing technique that promises to restore vision in patients with certain genetic forms of blindness. By utilizing CRISPR-Cas9 technology, scientists have been able to directly correct mutations in retinal cells. The preclinical models have shown restored function and improved visual responses, paving the way for human trials. This breakthrough is not just a beacon of hope for those affected by genetic blindness but also underscores the transformative potential of gene-editing technologies in treating complex diseases.Moving on to regulatory news, there's an update on new drug approvals that could have widespread implications for public health. The FDA has recently approved a first-in-class drug for the treatment of severe migraines. This medication represents a novel mechanism of action by targeting the calcitonin gene-related peptide (CGRP) pathway, which plays a crucial role in migraine pathophysiology. Clinical trials indicated that it significantly reduces the frequency and severity of migraine attacks compared to existing treatments. For millions of sufferers worldwide, this approval offers a new avenue for relief and highlights the importance of continued innovation in chronic pain management.Shifting gears to vaccine development, there's exciting progress in the fight against infectious diseases. A new vaccine candidate for malaria has shown an unprecedented level of efficacy in trial settings. This vaccine utilizes a protein-based approach that targets multiple stages of the parasite's lifecycle, thereby enhancing its protective effects. Given malaria's devastating impact globally, particularly in sub-Saharan Africa, this development is being hailed as a potential game-changer in global health efforts. As further studies and real-world evaluations unfold, this vaccine could become a cornerstone tool in reducing malaria's burden.Now turning our attention to industry trends, there's growing momentum around personalized medicine and its integration into mainstream healthcare systems. Personalized medicine tailors treatment strategies to individual patient profiles based on genetic, environmental, and lifestyle factors. Recent advances in genomics and data analytics have accelerated this shift, allowing for more precise and effective interventions. For healthcare providers and pharmaceutical companies alike, this trend necessitates rethinking traditional drug development models and embracing collaborative approaches to harness big data effectively.Finally, let's look at an intriguing development in neurodegenerative disease research. Scientists are exploring a new class of drugs designed to target protein misfolding—an underlying cause of conditions Support the show

In this episode of the Medical Sales Podcast, Samuel Adeyinka sits down with Bruce E. Brown, a seasoned sales professional with over 20 years in pharma who made a rare and successful transition into medical device sales as an independent 1099 distributor. Bruce shares how he broke away from the corporate structure, built his own LLC, and created a sustainable business by representing multiple product lines. He reveals unconventional but effective strategies for gaining access to surgeons and hospitals, lessons learned from the opioid era, and the realities of commission-only sales. This candid conversation offers a behind-the-scenes look at what it truly takes to survive, grow, and thrive as an independent medical sales professional.   Connect with Bruce E. Brown: LinkedIn Connect with Me: LinkedIn Love the show? Subscribe, rate, review, and share! Here's How »  

(0:00) Intro(3:36) “Today is your day with the Qur'an” — why he came to medical students(4:28) Who came by choice, who was dragged? An honest audience check(6:23) “Don't listen to what Pakistanis say” — social psychology 101(8:02) Warning: a high-potency “chemistry session” with side effects(9:18) Serotonin 101 — mother's tears and childhood emotional locking(13:01) Money, parents' reactions, and how success gets hard-wired(19:16) When you jump into the Qur'an, it lights up the whole country(20:42) Parliament, VIP protocols, and the side effects of leaving the Qur'an(24:30) Serotonin, titles, and why “Doctor” feels so powerful(32:02) Pharma, protocols, and SSRIs — who really controls thresholds?(40:00) Makeup, niqab, and female serotonin — confidence vs costume(48:05) Endowment effect — flags, clubs, and being “extra Pakistani”(53:05) Bharat Mata, Greater Israel, and why Islam isn't geographically locked(54:05) “You are more Pakistani and less Muslim” — identity breakdown(1:03:20) Pakistan, Pakistan, Pakistan — stuck in the national loop(1:10:04) Mission mode — Sahil as a “missionary” and why he looks for performers(1:18:21) Qur'an, stars, and science — why Muslims should lead global research(1:26:16) Doctors, research, and turning papers into real-world impact(1:32:20) IMS (Islamic Messaging System) platform and next steps for doctors Hosted on Acast. See acast.com/privacy for more information.

The following article of the Health industry is: “Mature Medicines: A Strategic Opportunity for Latin America” by Enrique Remezal, CEO, icon Group/Avanzia Pharma.

The most anticipated annual tradition on Out of Patients returns with the 2025 Holiday Podcast Spectacular starring Matthew's twins Koby and Hannah. Now 15 and a half and deep into sophomore year, the twins deliver another unfiltered year end recap that longtime listeners wait for every December. What began as a novelty in 2018 has become a time capsule of adolescence, parenting, and how fast childhood burns off.This year's recap covers real moments from 2025 A subway ride home with a bloodied face after running full speed into that tree that grows in Brooklyn. Broadway obsessions fueled by James Madison High School's Roundabout Youth Ensemble access, including Chess, & Juliet, Good Night and Good Luck, and Pirates of Penzance holding court on Broadway. A Disneylanmd trip where the Millennium Falcon triggered a full system reboot. A New York Auto Show pilgrimage capped by a Bugatti sighting. All the things.The twins talk school pressure, AP classes, learner permit anxiety, pop culture fixation, musical theater devotion, and the strange clarity that comes with turning 15. The humor stays sharp, the details stay specific, and the passage of time stays undefeated. This episode lands where the show works best: family, honesty, and letting young people speak for themselves.FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this solo episode, Shintaro Higashi breaks down five key lessons he's learned from decades of running and consulting for martial arts dojos, including NYC's Kokushi Budo Institute and Kano Martial Arts. From the power of soft skills to safety, cleanliness, and even why black belts should pay, this episode offers real-world dojo business insights for gym owners, instructors, and aspiring martial arts entrepreneurs.00:00 Introduction & Dojo Background01:00 Starting Kano Martial Arts & Consulting Experience02:00 Lesson 1: Soft Skills Matter More Than Credentials04:00 Applying Sales Techniques from Pharma to Martial Arts04:30 Lesson 2: Safety Is the Top Priority05:30 Risk Management & Eliminating Dangerous Techniques06:00 Why Safety Supports the Growth of Judo06:30 Lesson 3: Cleanliness & Hygiene Systems07:30 Enforcing Hygiene Rules & Student Accountability08:30 Lesson 4: Most Students Aren't Competitive Athletes09:30 Understanding Your Student Base & Why They Train10:30 Building an Inclusive, Supportive Dojo Culture11:30 Lesson 5: Even Black Belts Should Pay12:30 Retention Risks from Non-Paying Advanced Students13:30 Supporting Other Gyms as a Paying Visitor

Podcast: ICS Arabia PodcastEpisode: Pharma OT Security | 64Pub date: 2025-12-26Get Podcast Transcript →powered by Listen411 - fast audio-to-text and summarizationWe're joined by Andre Froneman, OT Solutions Specialist at Datacentrix — a cybersecurity professional with hands-on experience across the pharma, mining, automotive, and energy sectors.In this episode, we dive deep into pharmaceutical OT cybersecurity, exploring how one of the world's most sensitive industries protects its operations, data, and intellectual property from cyber threats.

Send us a textIn this episode, the boys present another of their popular Dynamite Conspiracies episodes, in which they ask if there is a "Sugar cover-up"?But what are your thoughts on this topic?Do you agree with Tony and Tayo on this?Or do you have other thoughts?Items used during the show:The "Sugar Cover-Up": In the 1960s, the sugar industry paid Harvard scientists (Project 226) to shift the blame for heart disease from sugar to saturated fat. This led to the "Low Fat" craze, where manufacturers removed fat from food but replaced it with massive amounts of sugar to make it taste good.The "Ancel Keys" Effect: Discuss the "Seven Countries Study." Keys famously cherry-picked data to prove fat was bad, conveniently leaving out countries (like France and West Germany) that ate lots of fat but had low heart disease.The "Profit" Motive: A cured diabetic buys no drugs. A managed diabetic is a customer for life. Is the push against "Keto" (which can reverse Type 2) actually about protecting pharmaceutical revenue?-https://diabetesjournals.org/care/article/34/Supplement_2/S132/28705/Hypoglycemia-and-Cardiovascular-Risks-https://news.un.org/en/story/2023/07/1138732Tune in and listen to the discussion. Please share your thoughts on these subjects.Although we greatly appreciate effusive praise on our Facebook page, we also welcome any feedback you might care to share, so please feel free to leave it. If your comments cause outrage or uproar, we'll likely have you on the show, as we're a bit unconventional in that regard.

Was, wenn eines der wirksamsten Heilmittel nie aus der Apotheke kam – und genau darüber jahrelang nicht gesprochen werden durfte? In diesem augenöffnenden Gespräch mit Dr. Roman Szeliga, Arzt und ehemaligem Pharma-Insider, öffnet sich Dir ein Blick hinter die Kulissen der Medizin. Du erfährst, warum Heilung weit mehr ist als Wirkstoffe und weshalb eine zutiefst menschliche Komponente systematisch unterschätzt wurde. Dr. Szeliga teilt Erfahrungen aus Krankenhäusern, die berühren, irritieren und ein völlig neues Verständnis von Gesundheit erahnen lassen. Am Ende bleibt eine Erkenntnis, die alles verändert – und die Dich unweigerlich fragen lässt, was Dir über Deine Gesundheit bisher verschwiegen wurde. Dr. Roman Szeligas Buch: "Hirn mit Herz hat Hand und Fuß" https://amzn.to/4geZnhL   Die geäußerten Meinungen und Aussagen dienen ausschließlich Bildungs- und Informationszwecken, ersetzen jedoch keine therapeutische oder medizinische Beratung. Bereit Dein Genie zu entdecken? Lebe selbstbewusster, freier & erfolgreicher mit genialen Video-Kursen aus unserer Online-Akademie: https://akademie.maximmankevich.com/  

Happy holidays once again! This is being aired the day after Christmas, or on Boxing Day for those who are in places that do a thing called Boxing Day. I guess it has something to do with giving boxes, or having boxes, or maybe relatives boxing one another after spending time together over the holidays. Whatever it is, hope you have a happy one. The actual origins, according to Wikipedia, seems to be around the mid 1700s when “traditionally on this day tradespeople, employees, etc., would receive presents or gratuities (a ‘Christmas box') from their customers or employers.” So maybe one of the earlier manifestations of customer and employee experience. One of the things that I love about doing experience design is how relatively small things can make someone feel like a superhero. Little acts of experience design can make a big difference in people's days and even their lives. And isn't that what it is all about, including the holidays? Whatever you believe or don't believe regarding the holidays, being mindful of extending small acts of kindness or doing something that is relatively simple to make a huge impact. Which is a perfect thing to keep in mind for our show today. My guest on Experience by Design is Erika Sinner. Erika brings a lot of compassion and empathy to the world. In fact, she prefers the title of Chief Empathy Officer. Her book Pets are Family emphasizes the importance of pet bereavement policies in organizations. This is just one part of her efforts to bring more empathy to the workplace. She also is the CEO and Founder of Directorie, “a(n) agency that connects seasoned commercial, marketing, and market access experts” with organizations that are under-resourced and overworked. If that wasn't enough, she now is the Chief Empathy Officer of Tiny Super Heroes, which makes children who are facing unique medical challenges to feel like the superheroes that they are. As their website states, “We're setting out to transform hospital culture - one hospital at a time - because every child's clinical journey should be filled with strength, hope, and a little more fun.”As part of Tiny Super Heroes, children get their own superhero capes and get badges to mark the medical treatments they receive as well as other accomplishments. It is all at no cost, and made possible through the donations of individuals and organizations, and aims to reach all 226 children's hospitals in the country.We talk about Erika's personal journey and struggles that led her to her work as a founder Directorie and now CEO of Tiny Super Heroes. We also talk about the importance of play in the workplace as a way of creating a sense of safety and trust. Talking about culture as a leader isn't enough; leaders need to take the necessary steps to create a place where employees don't dread Sunday nights because they have to go to work on Monday. She discusses the importance of company culture and employee commitment in attracting top talent, especially for Gen Z and Gen Alpha who prioritize making a difference.Erika discusses the positive impact of the Tiny Super Heroes program on children with medical conditions, highlighting how it helps reduce anxiety and improve clinical outcomes by transforming medical experiences into fun missions. The program has online support groups for parents, which currently have around 60,000 members. Healthcare providers also benefit from the program by creating a more positive and playful environment in hospitals. In this way, it is really an experience design that impacts the healthcare ecosystem.So on this Boxing Day, you can listen to this episode and head over to the Tiny Super Heroes website to give a gift that can make all the difference.Erika Sinner: https://www.linkedin.com/in/erikasinner/Erika Sinner Website: https://www.erikasinner.org/“Pets are Family” Book: https://www.erikasinner.org/for-bookstoreDirectorie: https://www.directorie.com/Tiny Super Heroes: https://tinysuperheroes.com/

Angel Studios https://Angel.com/HermanJoin the Angel Guild today where you can stream Thank You, Dr. Fauci and be part of the conversation demanding truth and accountability.  Renue Healthcare https://Renue.Healthcare/ToddYour journey to a better life starts at Renue Healthcare. Visit https://Renue.Healthcare/Todd Bulwark Capital https://KnowYourRiskPodcast.comBe confident in your portfolio with Bulwark! Schedule your free Know Your Risk Portfolio review. Go to KnowYourRiskPodcast.com today. Alan's Soaps https://www.AlansArtisanSoaps.comUse coupon code TODD to save an additional 10% off the bundle price.Bonefrog https://BonefrogCoffee.com/ToddThe new GOLDEN AGE is here! Use code TODD at checkout to receive 10% off your first purchase and 15% on subscriptions.LISTEN and SUBSCRIBE at:The Todd Herman Show - Podcast - Apple PodcastsThe Todd Herman Show | Podcast on SpotifyWATCH and SUBSCRIBE at: Todd Herman - The Todd Herman Show - YouTubeThe ultimate unholy union is government and healthcare. President Trump has put out some words on government and healthcare, and President Trump, is a good friend of big Pharma.Episode Links:Democrat Senator Peter Welch on Obamacare: "We did fail to bring down the cost of healthcare."American doctor goes over how Barack Obama destroyed American HealthcareObamacare is only 7% of Americans. Literally almost 100% of Americans need relief from their health care policy premiums, not just 7%. We need to have free market solutions that bring down the cost of health care for every American, not just the 7%.The Danish Cow Crisis: Bill Gates, “Bovaer,” and the War on Nature. In Denmark, farmers are raising alarms after a new climate-driven feed additive called Bovaer became mandatory on October 1, 2025.Virtually everything that Obama promised about Obamacare was a lie. Now the country is stuck dealing with the ramifications. Instead of taking responsibility, Democrats have shut down the government and are demanding that Republicans fix what they broke.

On this Christmas Eve edition of Badlands Daily, CannCon and Ashe in America take to the mic for a spirited, heartfelt, and wide-ranging conversation as they close out the holiday week with the Badlands community. The show blends festive moments with hard-hitting commentary, touching on government overreach, Big Pharma corruption, taxpayer-funded research scams, and the broader push to “equalize” America at the expense of its people. The hosts engage directly with the audience through rants and shout-outs, reflect on the year that was, and discuss ongoing investigations, election integrity issues, and the growing ability to speak more openly as censorship loosens. Along the way, they share holiday wishes, upcoming programming notes, and gratitude for the Badlands family that continues to show up every day. A Christmas Eve broadcast that balances humor, conviction, and community, this episode captures the spirit of Badlands Daily - truth-seeking, unapologetic, and rooted in faith, freedom, and fellowship.

Jason Gilley walked into adulthood with a fastball, a college roster spot, and a head of curls that deserved its own agent. Cancer crashed that party and took him on a tour of chemo chairs, pediatric wards, metal taste, numb legs, PTSD, and the kind of late night panic that rewires a kid before he even knows who he is.I sat with him in the studio and heard a story I know in my bones. He grew up fast. He learned how to stare down mortality at nineteen. He found anchors in baseball, therapy, and the strange friendships cancer hands you when it tears your plans apart. He owns the fear and the humor without slogans or shortcuts. Listeners will meet a young man who refuses to let cancer shrink his world. He fights for the life he wants. He names the truth without apology. He reminds us that survivorship stays messy and sacred at the same time. This conversation will stay with you.RELATED LINKS• Jason Gilley on IG• Athletek Baseball Podcast• EMDR information• Children's Healthcare of AtlantaFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Read our Macrovey deal analysis (closed) on KingscrowdRobotics hype is everywhere—but who actually makes robots work on real warehouse floors? In this episode, Chris sits down with Macrovey Director of Business Development Matt Labinski to unpack how Macrovey designs fully autonomous, material-handling systems that act like a warehouse “Robotics OS.” We start with what Macrovey is and isn't (00:03)—the company doesn't manufacture robots, it integrates best-in-class OEMs through proprietary orchestration software. Matt explains the model (00:32): up-front design + install and recurring software/maintenance—plus a Robots-as-a-Service option that lowers CapEx. We dive into who buys (06:28): e-commerce, 3PLs, pharma, defense (U.S. Air Force) and even smaller 10k–100k sq ft facilities. Category context (07:31): warehouse robotics penetration is still surprisingly low; Macrovey targets the SMB/mid-market others ignore. We cover why OEMs and warehouses need an integrator (09:09), the sales cycle and deal sizes (12:22)—from $50k pilots to $3M+ programs—and how modular, mobile systems (25:03) move with demand. Finally, we hit the AI layer (27:31): machine learning that optimizes slotting, picking, and vision-based QA. If you want exposure to warehouse autonomy without betting on a single robot, Macrovey's middle-layer, recurring-revenue approach may be the de-risked way to play it.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world.In a dynamic landscape marked by both advancements and challenges, the pharmaceutical and biotech sectors continue to evolve with notable scientific, regulatory, and strategic updates. Ipsen's recent $1 billion acquisition of Simcere's preclinical LRRC15-targeting asset underscores a growing focus on antibody-drug conjugates (ADCs). These conjugates leverage the targeted action of antibodies combined with the cytotoxic effects of drugs, representing a promising approach to cancer treatment by potentially minimizing systemic toxicity. Ipsen's strategic move reflects its commitment to expanding its oncology portfolio and staying competitive within the rapidly advancing ADC landscape.AstraZeneca has been active in its pursuit of innovative cancer treatments. The company has invested $100 million in Jacobio's clinical-stage pan-KRAS inhibitor, a promising development targeting KRAS mutations prevalent in various cancers. This investment aligns with AstraZeneca's strategy to tackle challenging oncogenic targets. However, their efforts faced a setback as their Phase 3 trial for ceralasertib, an ATR inhibitor for lung cancer, failed to meet its primary endpoint. Despite this setback, AstraZeneca maintains confidence by investing significantly in promising areas like KRAS inhibitors, highlighting the inherent risks involved in pioneering novel therapeutic strategies, particularly those aiming to overcome resistance mechanisms in immuno-oncology.BioMarin has quietly discontinued its liver disease candidate amid a $4.8 billion deal with Amicus. This decision points to the complex nature of pipeline prioritization and resource allocation within high-stakes financial environments. The company's strategic shifts reflect ongoing evaluations of their development priorities in light of evolving market demands.Boehringer Ingelheim has demonstrated a commitment to renal therapeutics with a $448 million investment in Rectify Pharmaceuticals for a preclinical chronic kidney disease program. This partnership seeks to address significant unmet medical needs within kidney disease treatment. Meanwhile, Gilead Sciences has entered into a $35 million licensing agreement with Assembly Biosciences for herpes simplex virus (HSV) assets, diversifying its infectious disease portfolio and expanding its reach within antiviral therapies.Novo Holdings-backed Windward Bio's acquisition of rights to Qyun's clinical-stage immunology bispecifics for $700 million highlights robust activity in the immunology space. Bispecific antibodies are gaining traction due to their ability to target two antigens simultaneously, offering enhanced therapeutic efficacy. This acquisition illustrates ongoing interest in this area as companies seek innovative solutions to complex immunological challenges.The broader industry is also witnessing strategic partnerships such as Aditum Bio's launch of a new biotech venture with Fosun Pharma. This collaboration aims to foster novel therapies through a synergistic blend of biotechnology innovation and pharmaceutical expertise. These alliances reflect an industry trend towards collaborative efforts that leverage diverse strengths to advance therapeutic development.In regulatory news, nine major pharmaceutical companies have reached agreements with the U.S. government to lower certain drug prices in exchange for tariff relief. This development signals ongoing negotiations aimed at balancing drug affordability with industry sustainability amid growing scrutiny over pricing practices.In December 2025, significant developments emerged, impacting scientific innovation, regulatory approvals, mergers, and strategic partnerships across the industry. Notably, the U.S. Food and Drug Administration (FDA) granted early approval to Cytokinetics' MyqorzSupport the show

This week, Isabel brings together three expert voices for an end-of-year round-up, reflecting on the moments that shaped healthcare and life sciences in 2025. Joined by Jonathan Sackier, Chairman, Medical Advisory Board, EMJ, Hanna Svanbäck, Executive Director for Neuroscience, Eli Lilly, and omnichannel expert Yacin Marzouki, the conversation looks back on a year defined by both disruption and progress. Across the episode, the contributors share their perspectives on the biggest setbacks and standout successes of the past 12 months, from regulatory uncertainty and access challenges to collaboration, innovation and scientific momentum. They also reflect on the lessons 2025 has taught them, and what those insights mean for patients, industry and the year ahead. Speaker bios Hanna Svanbäck Executive Director for Neuroscience, Eli Lilly With over 15 years at Eli Lilly, Hanna leads Neuroscience operations across the UK, Ireland and the Nordics, driving scientific innovation and patient-centred research. Jonathan Sackier Chairman, Medical Advisory Board, EMJ Jonathan is a surgeon by training and a founding partner of many start-ups in the medical technology space, as well as being the creator of the world's first operating room robot. Yacin Marzouki  Omnichannel expert Within the pharmaceutical sector, Yacin specialises in shaping seamless customer journeys, driving content activation and aligning global strategies with local execution.

2025 – what a year that was for medical marketing.So many events and developments contributed to headlines in not only MM+M but mainstream outlets as well.Chief among them was the confirmation of Robert F. Kennedy Jr. as HHS Secretary, which signaled the direction that the second Trump administration would take on health policy.Not to be outdone, AI had a sizable impact, too. The momentum behind AI affected how millions consume information, do their jobs and even the ads they see on a daily basis.  Additionally, the closing of Omnicom's takeover of IPG sent another shockwave through adland. Though medical marketing shops may be more insulated than consumer agencies, they were not spared.This week, I'm joined by editor-in-chief Jameson Fleming, editor-at-large Steve Madden, pharma editor Lecia Bushak and reporter Heerea Rikhraj so the MM+M editorial team can say ‘goodbye' to 2025 and ‘hello' to 2026 in our final episode of the year.And once again, in lieu of the Trends segment, we bring you an interview from our recent AI Deciphered conference, this time with health futurist John Duffield. Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.Music: “Deep Reflection” by DP and Triple Scoop Music. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The Eastman Kodak Company is ready for its closeup. The 130-year-old film company made big moves this year to bulk up its balance sheet and push into a brand new field - pharmaceuticals. Kodak completed a pension reversion in November, which unlocked $1 billion. The funds create a new pension fund, bringing debt down to $200 million, and put $300 million in cash on the balance sheet. The goal now - innovate. Kodak has always been a chemical company. Executives are using that expertise to move into the pharmaceutical industry. FOX Business's Lydia Hu speaks with Eastman Kodak Company executive chairman and chief executive officer Jim Continenza about how, while the company is still focused on film, it believes it has the expertise and infrastructure to grow by delving into pharmaceuticals. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Are you a nurse or healthcare professional feeling burned out, underpaid, and stuck in a cycle of bureaucracy?Today, I reveal the 3-3-3 Framework: a blueprint specifically designed for bedside nurses who want to break into the high-paying world of Pharmaceutical and Medical Device Sales.If you are tired of missing holidays and hitting a salary ceiling, this episode explains exactly what you actually need to do to land offers like our student Sydney, who went from $68k to a $138k package.IN THIS EPISODE, YOU WILL LEARN:The 3 Reasons to Leave: Why burnout and lack of creativity are signs it's time to pivot.The 3 Barriers: Why relying on your degree and "following orders" kills your chances in sales interviews.The 3 Solutions: How to leverage your clinical edge and tap into the 10,000+ open roles in biotech right now.READY TO LAND YOUR DREAM JOB? Apply to Medical Sales University and learn how we help nurses double their income in 12 weeks: medicalsalesu.com/TIMESTAMPS00:00 - Intro: The shift from Bedside to Sales01:38 - The 3 Reasons healthcare workers are leaving (Burnout & Bureaucracy)03:13 - Why your career growth has stalled04:10 - The 3 Barriers: Why you aren't getting hired yet05:00 - The "Middle Class Mindset" trap (Degree vs. Skills)06:12 - Mindset Shift: From Compliance to Ownership09:18 - The 3 Solutions: How to finally break in10:52 - Success Story: How Sydney landed a $138k Oncology role12:50 - Why mentorship beats doing it aloneABOUT THE HOST: Dave Sterrett is the founder of Medical Sales University, the #1 program helping nurses, PTs, and healthcare professionals break into pharmaceutical and oncology sales.ABOUT MEDICAL SALES U: Medical Sales U is the premier training program for professionals looking to break into high-paying careers in Medical Device, Pharmaceutical, and Genetic Testing sales. We turn "outsiders" into top 1% candidates.CONNECT WITH US:Learn more about coaching and career support at medicalsalesu.com/#MedicalSales #NursingCareer #PharmaSales #NurseBurnout #CareerChange #MedicalDeviceSales #HighPayingJobs #Nurselife

The Eastman Kodak Company is ready for its closeup. The 130-year-old film company made big moves this year to bulk up its balance sheet and push into a brand new field - pharmaceuticals. Kodak completed a pension reversion in November, which unlocked $1 billion. The funds create a new pension fund, bringing debt down to $200 million, and put $300 million in cash on the balance sheet. The goal now - innovate. Kodak has always been a chemical company. Executives are using that expertise to move into the pharmaceutical industry. FOX Business's Lydia Hu speaks with Eastman Kodak Company executive chairman and chief executive officer Jim Continenza about how, while the company is still focused on film, it believes it has the expertise and infrastructure to grow by delving into pharmaceuticals. Learn more about your ad choices. Visit podcastchoices.com/adchoices

In this episode of IDEA Collider, hosts Mike and Rick revisit a pivotal project from over a decade ago, the Reblozyl project, undertaken in collaboration with Acceleron and Celgene. Rick, the head of Growth and Innovation at IDEA, reminisces about the early days leading to the successful positioning and market shaping of luspatercept across different hematological indications. The episode features insightful contributions from Robin, Jane, and Tracy, key players from Acceleron and Celgene, who share their experiences and the collaborative efforts that enabled them to redefine the market. The discussion covers the strategic approach to overcoming competitive benchmarking, the importance of a unified messaging strategy, and the critical role of internal and external collaboration. They also reflect on the impact of their efforts on the lives of many patients and offer advice for future teams working on complex drug development projects. The episode concludes with a recognition of the rare and valuable collaborative human elements that drove the success of the Reblozyl project.Episode Timestamps;00:00 Introduction and Welcome00:27 Rick's Background and Project Overview02:31 Client Team Introductions05:32 Collaboration and Challenges13:29 Defining the Mechanism and Market Positioning23:52 Communication and Alignment27:48 Navigating Internal and External Communication33:15 Launch, Reflections, and Lessons Learned41:14 Final Thoughts and Acknowledgements Keep up with the guests;Robyn Blackburn  - Director Global Commercial Strategy CAR-T at Kite Pharmahttps://www.linkedin.com/in/robyn-blackburn-805b8b13/Jayne Butler - Director of Strategic Initiatives at Fingerpaint Brandinghttps://www.linkedin.com/in/jaynebutler/Tracey Sacco - Former SVP Global Strategic Marketing at Acceleronhttps://www.linkedin.com/in/tracey-sacco-53 2a034/Rick Ritacco - Head of Growth and Innovationhttps://www.linkedin.com/in/rritacco/ Follow Mike Rea On;Website: https://ideacollider.simplecast.com/X: https://x.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/ Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

The Eastman Kodak Company is ready for its closeup. The 130-year-old film company made big moves this year to bulk up its balance sheet and push into a brand new field - pharmaceuticals. Kodak completed a pension reversion in November, which unlocked $1 billion. The funds create a new pension fund, bringing debt down to $200 million, and put $300 million in cash on the balance sheet. The goal now - innovate. Kodak has always been a chemical company. Executives are using that expertise to move into the pharmaceutical industry. FOX Business's Lydia Hu speaks with Eastman Kodak Company executive chairman and chief executive officer Jim Continenza about how, while the company is still focused on film, it believes it has the expertise and infrastructure to grow by delving into pharmaceuticals. Learn more about your ad choices. Visit podcastchoices.com/adchoices

✅ Alles zum Thema Lithium: Hier klicken✅ Vollständiges Video von Dr. med. Michael Niels: Hier klicken

Join Eric, @EnglishNick67, @ShelleyWynter1, Steffan Pappas, @DrJoeEsposito, Santa, @TimAndrewsHere, @Autopritts, @JaredYamamoto, Greg, and George LIVE on 95.5 WSB from 3pm-7pm as they celebrate a merry Christmas during their very last show of the year with songs, trivia, laughter, joy and more! *New episodes of our sister shows: The Popcast with Tim Andrews and The Nightcap with Jared Yamamoto are available as well!

ByteDance signs a deal for a TikTok U.S. joint venture, The second Russia–Africa Partnership Ministerial Conference kicks off in Egypt, The EU agrees on a €90 billion loan to Ukraine, While the EU delays a Mercosur trade deal signing amid farmer protests, Australia launches a gun buyback after the Bondi Beach attack, Pharma companies agree to cut U.S. drug prices in a Trump administration deal, The suspect in the Brown University mass shooting and MIT professor murder is found dead, Trump Media merges with TAE in $6 billion fusion energy deal, Facebook tests limiting external links for non-verified accounts and U.K. actors vote overwhelmingly against digital scanning to train AI. Sources: Verity.News

Tune in as Glenn Hunzinger and Roel van den Akker share their outlook for pharmaceutical and life sciences dealmaking in 2026. They discuss improving market conditions, innovation driven growth, and how upcoming loss of exclusivity is shaping deal strategy.  Discussion highlights: Strong innovation, healthy balance sheets, and improving capital markets support a positive outlook for 2026 M&A is expected to remain precision-led and asset-focused, centered on differentiated science and key therapeutic areas Accelerating loss of exclusivity (2026–2029) is increasing reliance on external innovation Mid-sized deals have dominated, but clearer policy and better financing may enable larger strategic transactions As innovation globalizes, companies are sourcing assets more deliberately worldwide, with the US remaining a core life sciences hub Speakers: Glenn Hunzinger, US Health Industries Leader, PwC Roel van den Akker, US Pharmaceutical & Life Sciences Deals Leader, PwCLinked Materials:https://www.pwc.com/us/en/industries/health-industries/library/pharma-life-sciences-deals-outlook.htmlhttps://www.pwc.com/us/en/industries/health-industries/library/medtech-deals-outlook.htmlhttps://www.pwc.com/us/en/industries/health-industries/library/health-services-deals-outlook.htmlFor more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.

Die Antibabypille war eine medizinische und gesellschaftliche Revolution, doch seit über 60 Jahren gibt es sie nur für Frauen. Wieso eigentlich? In dieser 11KM-Folge erzählt uns NDR-Wissenschaftsjournalistin Daniela Remus, warum es trotz vielversprechender Ansätze bisher nicht gelungen ist, eine Pille für den Mann auf den Markt zu bringen – und welche gesellschaftlichen Veränderungen sie bringen würde. Tickets für 11KM auf dem ersten ARD Sounds Festival am 9. Mai 2026 in Nürnberg gibt es hier. Wir freuen uns, wenn ihr mit dabei seid! https://1.ard.de/11KM_ARD_Sounds_Festival Hier geht's zur Danielas Folge bei “IQ - Wissenschaft und Forschung”: https://www.ardaudiothek.de/episode/urn:ard:episode:999f4b089b8a2754/ In dieser früheren 11KM-Folge "Ei, ei, ei, die Spermakrise” beantworten wir die Frage, warum seit Jahren immer weniger Spermien im Ejakulat zu finden sind: https://1.ard.de/11KM_Spermakrise Hier geht's zu “Liebt euch – der UNSERDING Dating Podcast”, unserem Podcast-Tipp: https://www.ardaudiothek.de/sendung/liebt-euch-der-dating-podcast/urn:ard:show:178a60183a5a9d80/ An dieser Folge waren beteiligt: Folgenautor: Max Stockinger Mitarbeit: Lukas Waschbüsch Host: Elena Kuch Produktion: Timo Lindemann, Konrad Winkler, Hanna Brünjes und Marie-Noelle Svihla Planung: Caspar von Au und Hardy Funk Distribution: Kerstin Ammermann Redaktionsleitung: Fumiko Lipp und Nicole Dienemann 11KM: der tagesschau-Podcast wird produziert von BR24 und NDR Info. Die redaktionelle Verantwortung für diese Episode liegt beim BR.

Dr. Marissa Russo trained to become a cancer biologist. She spent four years studying one of the deadliest brain tumors in adults and built her entire research career around a simple, urgent goal: open her own lab and improve the odds for patients with almost no shot at survival. In 2024 she applied for an F31 diversity grant through the NIH. The reviewers liked her work. Her resubmission was strong. Then the grant system started glitching. Dates vanished. Study sections disappeared. Emails went silent. When she finally reached a program officer, the message was clear: scrub the DEI language, withdraw, and resubmit. She rewrote the application in ten days. It failed. She had to start over. Again. This time with her identity erased.Marissa left the lab. She found new purpose as a science communicator, working at STAT News through the AAAS Mass Media Fellowship. Her story captures what happens when talent collides with institutional sabotage. Not every scientist gets to choose a Plan B. She made hers count.RELATED LINKSMarissa Russo at STAT NewsNIH F31 grant story in STATAAAS Mass Media FellowshipContact Marissa RussoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. As we close out the year 2025, it's clear that the pharmaceutical and biotech industries have experienced a period of significant transformation. This year has been marked by groundbreaking drug approvals, strategic partnerships, and a focus on innovative therapies that promise to redefine patient care.One of the standout achievements this year comes from GlaxoSmithKline, which received approval from the U.S. FDA for its ultra-long-acting biologic, Exdensur, aimed at treating severe asthma with an eosinophilic phenotype in adolescents and adults. This approval underscores the growing trend toward personalized medicine and biologics, offering new hope for patients with chronic respiratory conditions by providing more sustainable and personalized treatment options.In the oncology sector, Merck's Keytruda and Astellas Pharma's Padcev have demonstrated significant overall survival benefits when used as perioperative treatments for cisplatin-eligible muscle-invasive bladder cancer. This combination therapy of a PD-1 checkpoint inhibitor and an antibody-drug conjugate highlights the evolving landscape of cancer treatment, emphasizing the role of immunotherapy and targeted therapies in improving patient outcomes in challenging cancer subtypes.However, not all developments have been positive. Hansa Biopharma faced challenges with its kidney transplant drug, imlifidase. Despite success in kidney transplant trials, it failed to achieve desired results in treating anti-glomerular basement membrane disease. This serves as a reminder of the complexities involved in drug repurposing efforts within autoimmune diseases.Alnylam Pharmaceuticals announced a significant investment to enhance its Norton, Massachusetts facility into a dedicated site for small interfering RNA (siRNA) production. This move reflects the industry's shift towards RNA-based therapies that offer targeted gene-silencing capabilities and positions Alnylam at the forefront of RNAi therapeutics production.In another promising development, ImmunityBio reported positive data from its QUILT-3.032 study on Anktiva for BCG-unresponsive non-muscle-invasive bladder cancer with high-grade papillary disease. The potential expansion of Anktiva's use reinforces the importance of personalized immunotherapies in oncology.The launch of Ambros Therapeutics with $125 million in Series A funding highlights efforts to develop non-opioid pain medications already approved abroad. This initiative addresses chronic pain management without relying on opioids, potentially advancing analgesic therapies amidst the ongoing opioid crisis.In China, Fosun Pharma's acquisition of a majority stake in Green Valley Pharmaceuticals aims to revive a controversial seaweed-derived Alzheimer's medication. Despite skepticism over its efficacy, this investment signals continued innovation efforts amid growing demand for effective Alzheimer's treatments.Siemens Healthineers' partnership with Alzpath to incorporate pTau-217 antibodies into its Atellica immunoassay platforms marks a significant step forward in Alzheimer's diagnostics. This collaboration aims to enhance biomarker detection capabilities crucial for early diagnosis and intervention strategies in neurodegenerative diseases.On the strategic front, Bristol Myers Squibb entered into a substantial research agreement with Harbour BioMed valued at up to $1.1 billion. This deal underscores Big Pharma's ongoing pursuit of alliances to advance therapeutic pipelines and antibody technologies.Finally, Cencora's acquisition of OneOncology for $5 billion underscores consolidation trends within specialty practice networks. By valuing OneOncology at $7.4 billion, this acquisition reflects the growing importance of integrated oncology care models and collaborative netSupport the show

Scott Capozza and I could have been cloned in a bad lab experiment. Both diagnosed with cancer in our early twenties. Both raised on dial-up and mixtapes. Both now boy-girl twin dads with speech-therapist wives and a lifelong grudge against insurance companies. Scott is the first and only full-time oncology physical therapist at Yale New Haven Health, which means if he catches a cold, cancer rehab in Connecticut flatlines. He's part of a small, stubborn tribe of providers who believe movement belongs in cancer care, not just after it. We talked about sperm banking in the nineties, marathon training during chemo, and what it means to be told you're “otherwise healthy” when your lungs, ears, and fertility disagree. Scott's proof that survivorship is not a finish line. It's an endurance event with no medals, just perspective.RELATED LINKSScott Capozza on LinkedIn: https://www.linkedin.com/in/scott-capozza-a68873257Yale New Haven Health: https://www.ynhh.orgExercising Through Cancer: https://www.exercisingthroughcancer.com/team/scott-capozza-pt-msptProfiles in Survivorship – Yale Medicine: https://medicine.yale.edu/news-article/profiles-in-survivorship-scott-capozzaFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Pharma Ads that Sound Ridiculous by Maine's Coast 93.1

Are you trying to break into medical sales but stuck deciding between Pharmaceutical and Medical Device? Or maybe you're curious about the high-growth world of Diagnostics and Genomics?Today, we discuss the differences in pay, lifestyle, and entry-level requirements for each path. Whether you want the adrenaline of the Operating Room or the stability of a $130k+ base salary in Pharma, this episode covers the 12 key distinctions you need to know before applying. IN THIS EPISODE YOU WILL LEARN:The Personality Test: Why "Engineers" love Device and "Scientists" love Pharma.The Paycheck: Real breakdown of base salaries vs. uncapped commissions.The Hidden Third Option: Why Oncology Diagnostics/Genomics might be the "Goldilocks" career path.Work-Life Balance: The reality of on-call surgical hours vs. the 9-to-5 pharma life.Success Stories: How a nurse (Sydney) and an immigrant (Kanika) broke in with $150k-$200k packages.READY TO BREAK IN? If you are struggling to get offers or don't know where to start, we help people from all backgrounds (nurses, coaches, teachers) launch their medical sales careers.Apply to Medical Sales U at medicalsalesu.com/TIMESTAMPS:00:00 - Intro: The common dilemma (O.R. vs. Samples).01:06 - The 3 Paths: Pharma, Device, and Diagnostics.02:15 - Science vs. Engineering: Which fits your brain?04:35 - Salary Reveal: Entry-level Pharma Pay ($95k-$135k base).06:10 - The "Associate" Role: Why Device base pay starts lower.07:40 - The Top 1%: Earning potential ($300k - $750k).09:15 - Diagnostics Pay: The sweet spot?10:30 - The Sales Process: Who are you actually selling to?13:50 - Lifestyle Check: Early mornings vs. Family flexibility.17:15 - Career Advancement: From Rep to Regional Director.22:15 - Student Success: From $68k to $200k total comp.ABOUT MEDICAL SALES U: Medical Sales U is the premier training program for professionals looking to break into high-paying careers in Medical Device, Pharmaceutical, and Genetic Testing sales. We turn "outsiders" into top 1% candidates.CONNECT WITH US:Learn more about coaching and career support at medicalsalesu.com/#MedicalSales #PharmaceuticalSales #MedDevice #SalesCareer #DaveSterritt #CareerAdvice #HighPayingJobs #SalesTips

Shannon Davis, a Registered Dietitian Nutritionist with more than 19 years of experience specializing in metabolic health and insulin resistance. She's a founding board member of the American Diabetes Society, an Insulin IQ Coach, and the founder of a successful virtual metabolic health practice where she's helped nearly a thousand people reverse insulin resistance, lose weight, and even put type 2 diabetes into remission. Shannon's background spans dialysis, organ transplant, bariatrics, and pharmaceutical sales — giving her a unique perspective on why food, not medication, is the real solution to most dietary conditions. She's been featured on over 50 podcasts as an expert in metabolic health, and when she's not helping people transform their lives, you'll find her in the gym doing CrossFit or spending time riding horses — her lifelong passion. Instagram: https://www.instagram.com/sldavis6580 X: https://x.com/fittoeat6580 YouTube: https://youtube.com/@shannondavis1619 Facebook: https://www.facebook.com/shannon.davis.9279 Website: https://shannonfeelgreat.com/ Timestamps: 00:00 Trailer 00:53 Introduction 05:31 Renal care challenges and ethics 09:11 Kidney health and low-carb diets 10:41 Keto and kidney care 13:44 Dialysis conflict of interest 18:39 Diabetes advocacy and carnivore 21:16 Ketogenic diets and diabetes 24:02 Preventing heart disease 28:16 Diet wars and social media 31:26 Better living through medication 34:04 Platform censorship frustrations  37:14 Grassroots health movement challenges 42:51 AI transforming pharmaceutical marketing 43:30 Drug industry priorities  49:16 Low carb diet and cholesterol 50:29 Where to find Shannon 53:43 United in the fight Join Revero now to regain your health: https://revero.com/YT Revero.com is an online medical clinic for treating chronic diseases with this root-cause approach of nutrition therapy. You can get access to medical providers, personalized nutrition therapy, biomarker tracking, lab testing, ongoing clinical care, and daily coaching. You will also learn everything you need with educational videos, hundreds of recipes, and articles to make this easy for you. Join the Revero team (medical providers, etc): https://revero.com/jobs ‪#Revero #ReveroHealth #shawnbaker  #Carnivorediet #MeatHeals #AnimalBased #ZeroCarb #DietCoach  #FatAdapted #Carnivore #sugarfree Disclaimer: The content on this channel is not medical advice. Please consult your healthcare provider.

Allie interviews Dr. Josef Witt-Doerring, a psychiatrist and former FDA drug safety officer. He unveils the truth about Big Pharma and the detrimental side effects of medications for mental illnesses. SSRIs cause more harm than good; they blunt emotions, breed dependency, and often backfire long-term. Dr. Witt-Doerring advises patients to pursue holistic health that includes a balanced diet, sleep, exercise, and therapy. He and his wife have started TaperClinic, where they help people come off medications and find real solutions to their problems. Join us for an eye-opening discussion about the dark side of the pharmaceutical industry. Check out more about Dr. Witt-Doerring's TaperClinic here: ⁠taperclinic.com⁠ Buy Allie's book "Toxic Empathy: How Progressives Exploit Christian Compassion": ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.toxicempathy.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ --- Timecodes: (00:00) Intro (09:45) Misdiagnosing Mental Illness (19:20) Drug Safety Officer (25:05) Corruption in Medical Academia (27:50) Wake-Up Call (34:35) Problems with SSRIs (46:00) Short-Term vs. Long-Term Medication (53:50) TaperClinic --- Today's Sponsors: PreBorn — Would you consider a gift to save babies in a big way? Your gift will be used to save countless babies for years to come. To donate, dial #250 and say the keyword BABY or donate securely at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠preborn.com/allie⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Good Ranchers — Give a reason to gather. Visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠goodranchers.com⁠⁠⁠⁠⁠⁠⁠⁠⁠ to start gifting, and while you're there, treat yourself with your own subscription to America's best meat. And when you use the code ALLIE, you'll get $40 off your first order. EveryLife — Visit ⁠⁠⁠⁠⁠everylife.com⁠⁠⁠⁠⁠ and use promo code ALLIE10 to get 10% off your first order today!  Patriot Mobile — Switching to Patriot Mobile is easier than ever. Activate in minutes from your home or office. Keep your number, keep your phone, or upgrade. Go to ⁠⁠⁠patriotmobile.com/allie⁠⁠⁠ or call 972-PATRIOT, and use promo code ALLIE for a free month of service! Cozy Earth — Give the gift of everyday luxury this holiday season. Head to ⁠cozyearth.com⁠ and use the code RELATABLE for up to 40% off — just be sure to place your order by December 12 for guaranteed Christmas delivery. --- Episodes you might like:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Ep 1189 | SSRIs Are Rewiring Babies' Brains — and Killing Their Moms | Guest: Dr. Adam Urato ⁠https://podcasts.apple.com/us/podcast/ep-1189-ssris-are-rewiring-babies-brains-and-killing/id1359249098?i=1000708507649⁠ Ep 821 | Why Antidepressants Don't Fix Depression | Guest: Dr. Roger McFillin ⁠⁠https://podcasts.apple.com/us/podcast/ep-821-why-antidepressants-dont-fix-depression-guest/id1359249098?i=1000616890403⁠⁠ Ep 822 | The Big Money Behind Big Medicine | Guest: Dr. Roger McFillin ⁠⁠https://podcasts.apple.com/us/podcast/ep-822-the-big-money-behind-big-medicine-guest-dr/id1359249098?i=1000617050991⁠⁠ Ep 1031 | Psychiatry Is Killing People | Guest: Dr. Roger McFillin ⁠⁠https://podcasts.apple.com/us/podcast/ep-1031-psychiatry-is-killing-people-guest-dr-roger/id1359249098?i=1000661830317⁠⁠ --- Buy Allie's book "You're Not Enough (and That's Okay): Escaping the Toxic Culture of Self-Love": ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.alliebethstuckey.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Relatable merchandise: Use promo code ALLIE10 for a discount: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://shop.blazemedia.com/collections/allie-stuckey⁠⁠⁠⁠⁠⁠⁠⁠⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

This episode features Olivier Godement, Head of Product for Business Products at OpenAI, discussing the current state and future of AI adoption in enterprises, with a particular focus on the recent releases of GPT 5.1 and Codex. The conversation explores how these models are achieving meaningful automation in specific domains like coding, customer support, and life sciences: where companies like Amgen are using AI to accelerate drug development timelines from months to weeks through automated regulatory documentation. Olivier reveals that while complete job automation remains challenging and requires substantial scaffolding, harnesses, and evaluation frameworks, certain use cases like coding are reaching a tipping point where engineers would "riot" if AI tools were taken away. The discussion covers the importance of cost reduction in unlocking new use cases, the emerging significance of reinforcement fine-tuning (RFT) for frontier customers, and OpenAI's philosophy of providing not just models but reference architectures and harnesses to maximize developer success. (0:00) Intro(1:46) Discussing GPT-5.1(2:57) Adoption and Impact of Codex(4:09) Scientific Community's Use of GPT-5.1(6:37) Challenges in AI Automation(8:19) AI in Life Sciences and Pharma(11:48) Enterprise AI Adoption and Ecosystem(16:04) Future of AI Models and Continuous Learning(24:20) Cost and Efficiency in AI Deployment(27:10) Reinforcement Learning and Enterprise Use Cases(31:17) Key Factors Influencing Model Choice(34:21) Challenges in Model Deployment and Adaptation(38:29) Voice Technology: The Next Frontier(41:08) The Rise of AI in Software Engineering(52:09) Quickfire With your co-hosts: @jacobeffron - Partner at Redpoint, Former PM Flatiron Health @patrickachase - Partner at Redpoint, Former ML Engineer LinkedIn @ericabrescia - Former COO Github, Founder Bitnami (acq'd by VMWare) @jordan_segall - Partner at Redpoint

Dr. MaryAnn Wilbur trained her whole life to care for patients, then left medicine behind when it became a machine that punished empathy and rewarded throughput. She didn't burn out. She got out. A gynecologic oncologist, public health researcher, and no-bullshit single mom, MaryAnn walked straight off the cliff her career breadcrumbed her to—and lived to write the book.In this episode, we talk about what happens when doctors are forced to choose between their ethics and their employment, why medicine now operates like a low-resource war zone, and how the system breaks the very people it claims to elevate. We cover moral injury, medical gaslighting, and why she refused to lie on surgical charts just to boost hospital revenue.Her escape plan? Tell the truth, organize the exodus, and build something that actually works. If you've ever wondered why your doctor disappeared, this is your answer. If you're a clinician hiding your own suffering, this is your permission slip.RELATED LINKSMaryAnn Wilbur on LinkedInMedicine ForwardClinician Burnout FoundationThe Doctor Is No Longer In (Book)Suck It Up, Buttercup (Documentary)FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Pharma deal, Supreme Court on piracy, special election in Nashville, and a TSA record. Plus, the Message of the Day, on heaven and hell… Learn more about your ad choices. Visit megaphone.fm/adchoices